Literature DB >> 12154380

Gene therapy of severe combined immunodeficiencies.

Alain Fischer1, Salima Hacein-Bey, Marina Cavazzana-Calvo.   

Abstract

The concept that the outcome of a devastating disease can be modified by inserting a transgene into abnormal cells is appealing. However, the gene-transfer technologies that are available at present have limited the success of gene therapy so far. Nevertheless, severe combined immunodeficiencies are a useful model, because gene transfer can confer a selective advantage to transduced cells. In this way, a proof of concept for gene therapy has been provided.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12154380     DOI: 10.1038/nri859

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  11 in total

1.  Theory and praxis of cloning via nuclear transfer: ;Never say never' or ;mission impossible'?

Authors:  Vittorio Sgaramella
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

2.  Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system.

Authors:  Xin Huang; Andrew C Wilber; Lei Bao; Dong Tuong; Jakub Tolar; Paul J Orchard; Bruce L Levine; Carl H June; R Scott McIvor; Bruce R Blazar; Xianzheng Zhou
Journal:  Blood       Date:  2005-09-27       Impact factor: 22.113

3.  Intrathymic administration of hematopoietic progenitor cells enhances T cell reconstitution in ZAP-70 severe combined immunodeficiency.

Authors:  Oumeya Adjali; Rita R Vicente; Christophe Ferrand; Chantal Jacquet; Cédric Mongellaz; Pierre Tiberghien; Karim Chebli; Valérie S Zimmermann; Naomi Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-07       Impact factor: 11.205

4.  Incorporation of DOPE into Lipoplexes formed from a Ferrocenyl Lipid leads to Inverse Hexagonal Nanostructures that allow Redox-Based Control of Transfection in High Serum.

Authors:  John P E Muller; Burcu S Aytar; Yukishige Kondo; David M Lynn; Nicholas L Abbott
Journal:  Soft Matter       Date:  2012-05-17       Impact factor: 3.679

5.  Distribution and clinical aspects of primary immunodeficiencies in a Taiwan pediatric tertiary hospital during a 20-year period.

Authors:  Wen-I Lee; Ming-Ling Kuo; Jing-Long Huang; Syh-Jae Lin; Cheng-Jang Wu
Journal:  J Clin Immunol       Date:  2005-03       Impact factor: 8.317

6.  In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer.

Authors:  Oumeya Adjali; Gilles Marodon; Marcos Steinberg; Cédric Mongellaz; Véronique Thomas-Vaslin; Chantal Jacquet; Naomi Taylor; David Klatzmann
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 7.  In vivo reversion to normal of inherited mutations in humans.

Authors:  R Hirschhorn
Journal:  J Med Genet       Date:  2003-10       Impact factor: 6.318

8.  ZAP-70 restoration in mice by in vivo thymic electroporation.

Authors:  Magali Irla; Murielle Saade; Adrien Kissenpfennig; Lionel Franz Poulin; Lee Leserman; Patrice N Marche; Evelyne Jouvin-Marche; François Berger; Catherine Nguyen
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

Review 9.  Allogeneic stem cell transplantation for treatment of immunodeficiency.

Authors:  Wilhelm Friedrich; Susanna M Müller
Journal:  Springer Semin Immunopathol       Date:  2004-09-11

Review 10.  Immune deficiencies due to defects in cytokine signaling.

Authors:  John Kelly; Warren J Leonard
Journal:  Curr Allergy Asthma Rep       Date:  2003-09       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.